Jason Silvers bought $32k of GENB
President & CFO at Generate Biomedicines, Inc.. 2,000 shares at an average of $16.00, traded Mar 2, 2026, filed Mar 2, 2026.
Score components
- +22RoleCFO
- +5Trade size$32k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- +10Price context0% above the 52-week low
- +15Cluster5 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +9.4%, 3m +6.6%, 6m +25.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-085898, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 2, 2026 | POpen-market purchase Common Stockindirect: By daughter | +500 | $16.00 | $8,000 | 500 | Mar 2, 2026 |
| Mar 2, 2026 | POpen-market purchase Common Stockindirect: By daughter | +500 | $16.00 | $8,000 | 500 | Mar 2, 2026 |
| Mar 2, 2026 | POpen-market purchase Common Stockindirect: By son | +1,000 | $16.00 | $16k | 1,000 | Mar 2, 2026 |
| Feb 26, 2026 | AGrant or award Stock Option (Right to Buy)derivative | +295,608 | $0.00 | $0 | 295,608 | Mar 2, 2026 |
| Feb 26, 2026 | AGrant or award Stock Option (Right to Buy)derivative | +274,493 | $0.00 | $0 | 274,493 | Mar 2, 2026 |
Related signals
Other insiders at Generate Biomedicines, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Generate Biomedicines, Inc. | Frances Arnold director | $16k 1,000 shares | -0% | |
| 63Notable | Generate Biomedicines, Inc. | Michael Nally Chief Executive Officer | $240k 20,000 shares | +4% | |
| 71Notable | Generate Biomedicines, Inc. | Noubar Afeyan director, owner | $75M 4,687,500 shares | +34% | |
| 71Notable | Generate Biomedicines, Inc. | Noubar Afeyan director, owner | $75M 4,687,500 shares | +34% | |
| 48Moderate | Generate Biomedicines, Inc. | Jane L Mendillo director | $24k 1,500 shares | - | |
| 48Moderate | Generate Biomedicines, Inc. | Beth Grous Chief People Officer | $4,800 300 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.